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Background. Common acute-term side effects of brain radiotherapy (RT) include fatigue, drowsiness, decreased physical function-
ing, and decreased quality of life (QOL). We hypothesized that armodafinil (a wakefulness-promoting drug known to reduce
fatigue and increase cognitive function in breast cancer patients receiving chemotherapy) would result in reduced fatigue and
sleepiness for patients receiving brain RT.
Methods. A phase II, multi-institutional, placebo-controlled randomized trial assessed feasibility of armodafinil 150 mg/day in
participants receiving brain RT, from whom we obtained estimates of variability for fatigue, sleepiness, QOL, cognitive function,
and treatment effect.
Results. From September 20, 2010, to October 20, 2012, 54 participants enrolled with 80% retention and 94% self-reported com-
pliance. There were no grade 4–5 toxicities, and the incidence of grade 2–3 toxicities was similar between treatment arms, the
most common of which were anxiety and nausea (15%), headaches (19%), and insomnia (20%). There were no statistically sig-
nificant differences in end-RTor 4 week post-RToutcomes between armodafinil and placebo in any outcomes (Functional Assess-
ment of Chronic Illness Therapy [FACIT]-Fatigue, Brief Fatigue Inventory, Epworth Sleepiness Scale, FACT-Brain, and FACIT-cognitive
function). However, in participants with more baseline fatigue, those treated with armodafinil did better than those who received
the placebo on the end-RT assessments for several outcomes.
Conclusion. Armodafinil 150 mg/day was well tolerated in primary brain tumor patients undergoing RT with good compliance.
While there was no overall significant effect on fatigue, those with greater baseline fatigue experienced improved QOL and re-
duced fatigue when using armodafinil. These data suggest that a prospective, phase III randomized trial is warranted for patients
with greater baseline fatigue.
Keywords: armodafinil, cognitive function, fatigue, primary brain tumors, radiotherapy.
Nearly 180 000 patients each year undergo brain radiotherapy (RT)
for either metastatic or primary brain tumors1 Radiation-induced
fatigue, drowsiness, and decreased physical functioning represent
some of the most common problems facing patients who receive
brain RT and can significantly worsen their quality of life (QOL). A
recent European Organisation for Research and Treatment of
Cancer (EORTC) randomized trial has demonstrated that patients
who receivewhole brain radiotherapy (WBRT) experience aworsen-
ing of performance status, in part due to fatigue.2 Thisworsening of
performance status can affect significant clinical decision-making
such as when or whether to offer chemotherapy. Pharmaceutical
intervention for radiation-induced fatigue has been attempted in
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multiple prospective clinical studies.3 Psychostimulants have been
previously assessed in patients who have been medically ill as
well as in brain tumor patients.4–8 Specifically with regard to pa-
tients receiving brain RT,methylphenidate, a substituted phenethyl-
amine psychostimulant commonly used in the treatment of
attention deficit/hyperactivity disorder, has been tested for QOL, fa-
tigue, andmental status. A recent phase III study assessing the ef-
ficacy of methylphenidate showed no benefit in QOL, fatigue
scores, and mental status in participants who received RT to the
brain.9 Other psychostimulants have been considered for theman-
agement of patients suffering from psychoneurological sequelae of
various medical conditions. Modafinil, a CNS stimulant, is a US
FDA-approved drug often utilized for wakefulness in conditions
such as narcolepsy or sleep apnea. Modafinil has a unique pharma-
cologic mechanism in that it is not known to bind to receptors for
sleep/wake regulation and does not inhibit MAO-B or phosphodies-
terases II–IV. Modafinil does not appear to affect dopaminergic ac-
tivity. Co-administration of modafinil with other CNS-active drugs
such asmethylphenidate and dextroamphetamine does not signif-
icantly alter the pharmacokinetics of either drug.10–12 In one ran-
domized study,modafinil was found to reduce fatigue and increase
cognitive function in breast cancer participants receiving chemo-
therapy.13 In a non–placebo-controlled pilot study,modafinil dem-
onstrated longitudinal improvement in cognitive, mood, and
fatigue outcome measures in primary brain tumor participants.14
However, modafinil 200 mg daily, did not have a significant effect
on QOL, cognitive function, depression, or fatigue for 37 primary
brain tumor participants in a randomized trial in the Netherlands.15
An additional randomized study of modafinil versus methylpheni-
date showed no difference between the modafinil or methylpheni-
date groups in brain tumor participants.16
Armodafinil is the R-enantiomer of modafinil and, unlike
modafinil, is a mixed dopamine receptor antagonist and dopa-
mine reuptake inhibitor, making it more effective as a CNS stim-
ulant than modafinil. It is also FDA approved for treating
excessive somnolence caused by narcolepsy, obstructive
sleep apnea, and shift work sleep disorders. As themechanisms
for somnolence caused by sleep disorders and brain RT are
thought to be similar, there has been significant interest in
the use of armodafinil for radiation-induced fatigue. Because
of the clinical need, the ineffectiveness of methylphenidate in
a randomized trial, and the prior mixed results of modafinil in
prospective clinical trials, we elected to perform a double
blind, placebo-controlled randomized study of armodafinil
verus placebo in patients receiving brain RT.
Methods
Participants/Eligibility and Exclusion Criteria
The study was approved by an appropriate institutional review
board and was conducted in accordance with the ethical stan-
dards laid down in the 1964 Declaration of Helsinki and its later
amendments. Patients were provided appropriate informed
consent prior to participating. Participants included patients
with malignant or benign/low-grade primary brain tumors re-
ceiving either partial or WBRT. (Only participants with medullo-
blastoma received RT to the whole brain.) Participants were
enrolled consecutively. Inclusion criteria were age ≥18 years,
primary brain tumor (benign, low grade or high grade), planned
whole or partial brain RT at a dose of at least 45 Gy at ≥1.5 Gy
per fraction, KPS ≥60%, and serum hemoglobin ≥10 g/dL. Con-
current chemotherapy was allowed. Patients with pre-existing
severe headaches were excluded from enrollment.
Treatment
The 150 mg/day dose of armodafinil was based on 3 random-
ized control trials of obstructive sleep apnea17,18or narcolepsy.19
All 3 studies showed a significant reduction in moderate-to-
severe fatigue and clinically significant sleepiness (compared
with participants who received placebo) with both the 150 mg/
day and 250 mg/day doses of armodafinil. Based on the clinical
data, the armodafinil dose for the proposed studywas chosen to
be 150 mg/day.
Trial Design and Treatment
This multi-institutional study was a placebo-controlled, random-
ized trial with a 1:1 allocation of primary brain tumor patients
receiving RT. After randomization, each participant received a
bottle of pills containing either the study drug (armodafinil
50 mg tablets) or placebo (identical-appearing pills). Both the
study drug and placebo were to be taken 3 at a time once
daily (totaling 150 mg per day for those on the study drug) for
7 days a week during the duration of RT and then an additional
4 weeks after RT. Participants had to begin the study drug by the
fifth fraction of RT. There were no dosemodifications or drug hol-
idays allowed for toxicity. If participants did not tolerate the
study agent, the agent was discontinued.
Fatigue, QOL, and cognitive function were assessed at base-
line, at the end of RT, and 4 weeks after RT by a trained research
nurse. A second brief self-report of fatigue was administered
weekly during RT. These visits were coordinated by a research
nurse and were generally on the same day as the participant’s
planned visit with the physician. Participants completed self-
administered fatigue and QOL questionnaires, and cognitive
function tests were performed by the trained research nurse.
Toxicities were recorded at baseline, weekly during radiation,
during the last week of radiation, and weekly during the
4-week postradiation follow-up. Toxicities were graded using
CTCAE version 4.0 criteria and were recorded on a flow sheet
as part of the physician assessment.
Study Settings and Study Instruments
Fatigue was measured by the Fatigue subscale of the Functional
Assessment of Chronic Illness Therapy-Fatigue subscale (FACIT-F)
and the Brief Fatigue Inventory (BFI). Sleepiness was measured
with the Epworth Sleep Scale (ESS). QOL, including brain-specific
symptoms, was measured by the FACT-Brain (Functional Assess-
ment of Cancer Therapy). Cognitive function was measured by a
standardized battery of validated tests of key domains of cogni-
tion.20–23 Tests included Verbal Fluency-Category (VF-C)
(Animals), Hopkins Verbal Learning Test-Revised (HVLT- R), Trail
Making Tests Parts A and B (TMT-A and TMT-B), and Digit Span
Test-Backwards (DST-B). The VF-C test24measures speed of men-
tal processing, verbal fluency, and executive functions. The
HVLT-R25 measures verbal learning and episodic memory. The
TMT-A and TMT-B26 measure attention, concentration, and visual
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motor speed. The DST-B27 assesses attention, concentration, and
working memory. The FACIT-F subscale21 has 13 fatigue-specific
items. The BFI28 is a rapid assessment of fatigue that includes
several visual analogue scales as well as questions that assess
the impact of the patient’s fatigue on QOL. The ESS29 is a mea-
sure of daytime sleepiness in which patients record their likeli-
hood of dozing or sleeping during a number of routine daily
activities.
Outcomes and Statistical Analysis
The primary objective of this randomized phase II trial was to
assess the feasibility of using armodafinil to reduce fatigue in
primary brain tumor patients undergoing brain RT. Secondary
objectives were to estimate the rate of toxicity or adverse
events associated with armodafinil, to estimate the variability
of the fatigue, QOL, and cognitive function outcomes, and to
obtain preliminary estimates of the effect of armodafinil
on these outcomes. Participants were stratified by KPS
(60%–80% vs 90%–100%) and whether or not they had
received chemotherapy and were assigned with equal probabil-
ity to armodafinil or placebo using variably sized permuted
block randomization.
The sample size of 54 participants allowed us to detect a
0.80 standard deviation difference in fatigue between the
treatment arms with 80% power at the 5% 1-sided level of sig-
nificance, assuming a 25% loss to follow-up as derived from
previous clinical trial retention rates.9,30 Means, standard devi-
ations, and pre/post correlations, useful for subsequent sample
size calculations, were provided for each outcome measure at
each time. Chi-square and Fisher exact tests were used to as-
sess treatment differences in toxicities. Mixed effects repeated
measures models were used to assess treatment differences in
fatigue, ESS, QOL, and cognitive function and to obtain least
squares (LS) estimates of the measures over time. An unstruc-
tured covariance matrix was used to model the correlation in
outcomes over time. The models were constrained to have
equal group means at baseline as detailed by Fitzmaurice
et al31 These models use all the data with the assumption
that missing data are missing at random. Additional mixed ef-
fects repeated measures analysis of covariance models were
used, which included baseline levels of fatigue to determine if
the effect of the treatment was consistent across initial fatigue
levels. Results are presented as LS means and standard errors
for each treatment arm as well as 90% 2-sided confidence lim-
its (since we planned to test the primary outcome at the 5%
1-side level of significance). Because this was a small pilot
study, we did not adjust P values or confidence limits for mul-
tiple comparisons.
Results
Patient Accrual and Treatment Compliance
From September 2010 until October 2012, a total of 54 patients
in multiple community and academic institutions were enrolled
and randomized to either armodafinil (n¼ 26) or placebo
(n¼ 28). Baseline patient characteristics are summarized in
Table 1 by treatment arm. Ages ranged from 20–79 years
with a median of 59 years; 40 (74%) were aged ≥50 years,
and 26 (48%) were aged ≥60 years. Most participants were
non-Hispanic whites (93%), and most (75%) had a KPS of
≥80%. Slightly more than half (54%) of the participants were
women, and 74% percent were within the CDC-defined
overweight-to-obese BMI range. The most common brain
tumor types were glioblastoma multiforme in 61%. Participant
characteristics did not differ significantly between treatment
groups. The retention rate was 85% in the armodafinil arm
and 89% in the placebo arm by the end of RT and 85% and
75%, respectively, at study completion. The self-reported com-
pliance was 94% while on therapy and did not differ between
treatment arms (P¼ .55). Of those participants who dropped
out of the study, reasons included progression of disease (n¼
1 armodafinil), refusal of further therapy (n¼ 1 armodafinil, n¼
2 placebo), toxicity (n¼ 2 placebo), death (1 participant in each
arm), and other (1 participant in each arm). There were no
Table 1. Baseline patient characteristics
Characteristic Armodafinil
No (%)
Control
No (%)
Total 26 (100) 28 (100)
Age (y)
Median (range) 59 (28–78) 58 (20–79)
Age ≥50 21 (81) 19 (68)
Age ≥60 13 (50) 13 (46)
Body mass index
Median (range) 27.7 (21.5–47.2) 28.3 (19.4–41.8)
Underweight-normal (,25) 8 (31) 6 (21)
Overweight (25–30) 6 (23) 12 (43)
Obese (≥30) 12 (46) 10 (36)
Performance status strata
1 – PS 60–80, no chemo 1 (4) 2 (7)
2 – PS 60–80, chemo 14 (54) 15 (54)
3 – PS 90–100, no chemo 3 (12) 4 (14)
4 – PS 90–100, chemo 8 (31) 7 (25)
Karnofsky performance status
60 3 (12) 1 (4)
70 3 (12) 7 (25)
80 9 (35) 9 (32)
90 10 (38) 6 (21)
100 1 (4) 5 (18)
Sex
Female 14 (54) 15 (54)
Male 12 (46) 13 (46)
Race/ethnicity
Hispanic 1 (4) 0 (0)
Asian 0 (0) 1 (4)
Black 0 (0) 2 (7)
White 25 (96) 25 (89)
Histology
Glioblastoma multiforme 15 (58) 18 (64)
Meningioma 5 (19) 2 (7)
Other* 6 (24) 8 (30)
*Other: Anaplastic astrocytoma, anaplastic oligoastrocytoma, low-grade
astrocytoma, low-grade oligodendroglioma, atypical meningioma,
medulloblastoma, pituitary adenoma, gliosarcoma.
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significant differences in patients in either groupwhowere taking
concomitant medications that may affect sleepiness, including
chemotherapy, steroids, antidepressants, sedatives, or benzodi-
azepines. These are represented in Supplementary Table S1.
Toxicity
Headache was the most common complaint and was experi-
enced to some degree by 73% of the armodafinil participants
and 59% of the control participants (P¼ .39). Insomnia
occurred in 46% and 52% of the armodafinil and con-
trol groups, respectively (P¼ .79), nausea in 46% and 48%
(P. .99), anxiety in 58% and 37% (P¼ .17), arthralgia in 12%
and 26% (P¼ .29), dizziness in 35% and 30% (P¼ .77), dry mouth
35% and 33% (P. .99), sinusitis in 4% and 11% (P¼ .61), sore
throat in 23% and 19% (P¼ .74), and upper respiratory infection
in 8% and 11% (P. .99). The most common grade 2+ toxicities
reported included 15% anxiety, 15% nausea, 19% headaches,
and 20% insomnia. There were 10 serious adverse events, 4 of
which were possibly related to treatment. These included 3
events on the placebo arm; (one grade 2 seizure, one grade 3 in-
crease in liver function tests, one grade 4 agitation/personality
change). On the armodafinil arm, a single participant experi-
enced a grade 3 headache with associated chest pain.
Fatigue and Sleepiness
Fatigue and sleepiness outcomes are summarized in Table 2.
Note that higher FACIT-fatigue values indicate less patient fa-
tigue, while higher BFI and ESS values indicate worse fatigue
and sleepiness, respectively. Fatigue levels worsened during ra-
diation and improved following completion of radiation on both
arms. Sleepiness improved slightly for armodafinil participants
but worsened slightly for the control participants. Results of the
mixed model analyses are summarized in Table 3. There were
no statistically significant differences between the placebo and
armodafinil groups in either fatigue outcomemeasure at either
time point (one-sided P value of .635 and .449 for FACIT_F and
BFI, respectively). Additionally, there was no significant change
in ESS over time, and the 2 groups were similar at each time.
In the mixed effects covariance model, we noted a significant
interaction between baseline fatigue and treatment, indicating
that the effect of treatment was not consistent across initial
fatigue levels. We subsequently dichotomized baseline fatigue
at the median level and repeated analyses for those with great-
er or lesser baseline fatigue (Table 3). For those participants who
presented with worse fatigue at baseline, treatment with armo-
dafinil resulted in significantly improved fatigue compared with
those receiving placebo. However, the opposite was true for
those participants with lesser fatigue levels at baseline; partici-
pants receiving placebo reported significantly less fatigue.
Quality of Life
QOL outcomes are summarized in Table 4. None of the QOL
outcomes differed significantly between treatment arms at
the end of RT or at 4 weeks post RT. These analyses were
repeated, stratified by baseline fatigue level (Table 5). In
those participants with greater fatigue at baseline, there was
a statistically significant advantage of armodafinil for the
total FACT-BR score (P, .001) at the end of RT. This was driven
by differences in the functional (P¼ .003) and physical (P¼
.001) subscale scores. Among participants with less fatigue at
baseline, those receiving armodafinil were significantly worse
for the functional subscale (P¼ .006) at the end of RT. None
of the other subscale scores differed significantly between
treatment arms.
Neurocognitive Function
Neurocognitive outcomes are summarized in Table 6. In gene-
ral, the scores on most cognitive tests improved slightly
over time in both groups. However there were no significant
differences between treatment arms at the end of RT or at
4 weeks post RT for any of the neurocognitive tests. Armodafinil
also did not improve neurocognitive outcomes at the end of RT
or at 4 weeks post RT in the subsets of participants with high or
low levels of fatigue at baseline.
Table 2. Summary of fatigue and sleepiness (raw data) by treatment and time
Outcome Time Armodafinil Control
No Mean SD Correlation* No Mean SD Correlation*
FACIT-Fatigue Baseline 26 34.0 10.9 27 38.3 11.6
EndRT 19 31.4 12.2 0.18 23 34.1 13.0 0.68
4wpRT 20 32.4 12.2 20.12 20 38.8 11.5 0.72
BFI Baseline 26 3.45 2.39 27 2.51 2.11
EndRT 21 3.90 2.74 0.44 25 3.70 2.87 0.38
4wpRT 21 3.76 2.74 0.52 21 2.67 2.72 0.32
ESS Baseline 26 8.62 4.41 27 6.85 3.90
EndRT 19 7.32 4.24 0.37 25 7.75 4.53 0.32
4wpRT 20 7.40 5.60 0.27 20 7.70 3.63 0.37
Abbreviations: 4wpRT, 4 weeks post radiation therapy; BFI, Brief Fatigue Inventory; EndRT, end of radiation therapy assessment; ESS, Epworth
Sleepiness Scale; FACIT, Functional Assessment of Chronic Illness Therapy;SD, standard deviation.
Higher scores in the FACIT indicate better symptoms. Higher scores in the BFI and ESS indicate worse symptoms.
*Pearson correlations with baseline.
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Table 3. Least squares estimates of fatigue and sleepiness at each time and post-randomization treatment differences
Outcome Time Armodafinil Control Difference in LS Mean (90% CI)
LS Mean (SE) LS Mean (SE)
FACIT-Fatigue Baseline 36.2 (1.55) 36.2 (1.55) —
EndRT 30.9 (2.74) 32.1 (2.56) 21.25 (27.28 to 4.78)
4wpRT 32.0 (2.56) 36.0 (2.52) 23.99 (29.86 to 1.88)
BFI Baseline 2.97 (0.32) 2.97 (0.32)
EndRT 3.88 (0.58) 3.97 (0.54) 20.10 (21.38 to 1.18)
4wpRT 3.71 (0.57) 3.29 (0.55) 0.42 (20.85 to 1.69)
ESS Baseline 7.72 (0.59) 7.72 (0.59)
EndRT 7.70 (1.02) 8.24 (0.92) 20.54 (22.77 to 1.70)
4wpRT 7.26 (1.03) 8.37 (1.00) 21.11 (23.47 to 1.26)
Greater fatigue at baseline
FACIT-Fatigue Baseline 27.1 (1.89) 27.1 (1.89) —
EndRT 31.5 (2.53) 23.2 (3.28) 8.24 (2.16–14.3)
4wpRT 31.9 (3.45) 28.3 (5.10) 3.62 (26.56 to 13.8)
Lesser fatigue at baseline
FACIT-Fatigue Baseline 44.7 (0.77) 44.7 (0.77) —
EndRT 24.9 (4.74) 38.8 (3.15) 213.9 (223.6 to 24.11)
4wpRT 29.2 (3.92) 41.4 (2.77) 212.2 (220.4 to 24.02)
Abbreviations: 4wpRT, 4 weeks post radiation therapy; BFI, Brief Fatigue Inventory; CI, confidence interval; EndRT, end of radiation therapy
assessment; ESS, FACIT, Functional Assessment of Chronic Illness Therapy; LS, least squares; SE, standard error Epworth Sleepiness Scale.
Lower scores in the FACIT-Fatigue indicate worse symptoms, while higher scores in the BFI and ESS indicate worse symptoms.
Table 4. Summary of quality of life outcomes (raw data) by treatment and time
Outcome Time Armodafinil Control
No Mean SD Correlation* No Mean SD Correlation*
Social Baseline 26 24.8 3.29 27 23.3 4.09
EndRT 19 23.4 4.39 0.62 25 22.1 5.59 0.72
4wpRT 20 23.1 3.99 0.58 20 22.6 5.12 0.71
Emotional Baseline 26 16.3 5.47 27 18.8 3.51
EndRT 20 18.3 3.76 0.64 25 18.3 4.27 0.62
4wpRT 20 17.7 2.89 0.51 20 19.5 3.68 0.41
Functional Baseline 26 13.7 7.63 27 17.7 5.98
EndRT 20 13.8 7.16 0.53 25 16.2 6.96 0.78
4wpRT 20 15.5 6.44 0.46 20 17.3 6.82 0.73
Physical Baseline 26 20.7 4.75 27 23.8 3.85
EndRT 20 19.4 5.71 0.23 25 19.8 5.67 0.54
4wpRT 20 20.3 6.53 0.13 20 23.2 4.13 0.63
FACT-G Baseline 26 75.4 16.1 27 83.6 13.7
EndRT 19 75.3 14.2 0.57 25 76.4 16.3 0.82
4wpRT 20 76.7 15.6 0.50 20 82.4 16.2 0.76
Brain Baseline 26 57.8 16.5 27 66.5 13.7
EndRT 19 62.5 15.2 0.81 25 67.5 15.3 0.83
4wpRT 20 62.5 12.5 0.66 20 69.8 16.0 0.78
FACT-Br Baseline 26 133.2 30.6 27 150.2 25.0
EndRT 19 137.8 27.5 0.74 25 143.9 29.9 0.89
4wpRT 20 139.2 26.8 0.61 20 152.2 30.3 0.79
Abbreviations: 4wpRT, 4 weeks post radiation therapy; EndRT, end of radiation therapy assessment; FACT, Functional Assessment of Cancer
Therapy; SD, standard deviation.
Social, Emotional, Functional, and Physical are the core components of the FACT quality of life questionnaire. FACT-G is the sum of the 4 compo-
nents. FACT-Br is the sum of FACT-G and the brain function subscale. Higher scores indicate better function in each of these measures.
*Pearson correlations with baseline.
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Discussion
Fatigue has been shown to be a prominent symptom that
leads toworsening QOL in brain tumor patients.32,33Multiple ran-
domized trials have now demonstrated that fatigue is worsened
by WBRT. The EORTC 22952 study comparing surgical or radio-
surgical management with WBRT in participants with brain me-
tastases revealed a clinically significant mean difference of 11.9
points in FACIT-F in theWBRTarm by 8 weeks postWBRT.2 A prior
EORTC phase III study of prophylactic cranial irradiation in exten-
sive stage small cell lung cancer also demonstrated that the par-
ticipants who received WBRT experienced worsened fatigue
scores.26 Prospective data demonstrating the degree of fatigue
in patients with partial brain irradiation are scarce. In a recent
prospective study ofmixed primary andmetastatic brain tumors,
a mean 3-point decrease in FACIT-F scores was detected be-
tween baseline and completion of partial or WBRT.9 Several pro-
spective studies have evaluated the efficacy of CNS stimulants
for the treatment of radiation-induced fatigue. In the same
study by Butler et al, a randomized trial of methylphenidate
was performed in participants with primary brain tumors who re-
ceived brain RT.9 While this study was negative, there have been
anecdotal reports of patients responding to methylphenidate.5,6
Modafinil is another CNS stimulant that has gathered interest.
While the exact mechanism of modafinil for relief of fatigue is
unknown, there has been significant interest in wakefulness-
promoting drugs for radiation-induced fatigue. Kaleita et al
performed a pilot study of 30 participants with primary brain tu-
mors that assessed the efficacy of modafinil using cognitive
function, mood, and fatigue measures.14 In this pilot study,
87% of participants received RT.
The current trial represents the first randomized trial evalu-
ating armodafinil for radiation-induced fatigue. While there
was no overall difference detected in fatigue between the 2
arms, participants who had worsened baseline fatigue scores
and were assigned to armodafinil treatment experienced stat-
istically significant improvements in fatigue at the end of radi-
ation. There was a corresponding improvement in QOL scores
as measured by the FACT-Br in this subpopulation, possibly
due to the improvement in fatigue. Interestingly, the partici-
pants who had significantly less fatigue at baseline were
found to have worse fatigue measures in the armodafinil
group versus the placebo group. It is unclear how to attribute
this difference, but it does not appear to be related to any wors-
ened side effects of armodafinil because the participants with
less fatigue were found to have the same rate of adverse side
effects as those with more fatigue at baseline. Preliminary re-
sults of another recent trial of armodafinil for radiation-induced
fatigue in participants with malignant gliomas were recently
presented at the American Society of Clinical Oncology national
meeting in 2014. The investigators found a nonsignificant trend
(P¼ .07) for improved FACIT-F scores among 80 participants.34
Neither study assessing armodafinil showed any difference be-
tween armodafinil and placebo with regard to toxicity. The
Table 5. Least squares estimates of selected quality of Life outcomes at each time and post-randomization treatment differences stratified by
baseline fatigue
Outcome Time Armodafinil Control Difference in LS Means (90% CI)
LS Mean (SE) LS Mean (SE)
Greater fatigue at baseline
Functional Baseline 11.9 (1.20) 11.9 (1.20) —
EndRT 15.4 (1.45) 8.8 (1.73) 6.59 (3.25–9.92)
4wpRT 15.7 (1.66) 11.0 (2.25) 4.75 (0.31–9.19)
Physical Baseline 19.3 (0.89) 19.3 (0.89) —
EndRT 20.4 (1.25) 13.4 (1.52) 7.01 (3.84–10.19)
4wpRT 20.5 (1.47) 19.6 (2.14) 0.85 (23.41 to 5.12)
FACT-G Baseline 70.2 (2.72) 70.2 (2.72) —
EndRT 75.0 (2.76) 58.9 (3.25) 16.17 (10.12–22.22)
4wpRT 75.3 (3.55) 70.0 (4.90) 5.29 (24.17–14.75)
Lesser fatigue at baseline
Functional Baseline 19.0 (1.26) 19.0 (1.26) —
EndRT 12.0 (1.93) 18.0 (1.50) 26.00 (29.42 to 22.58)
4wpRT 15.1 (2.13) 17.1 (1.67) 22.02 (26.04 to 2.01)
Physical Baseline 24.7 (0.54) 24.7 (0.54) —
EndRT 18.2 (1.85) 22.0 (1.27) 23.74 (27.57 to 0.09)
4wpRT 19.7 (1.98) 23.4 (1.45) 23.61 (7.78–0.57)
FACT-G Baseline 87.1 (2.45) 87.1 (2.45) —
EndRT 71.7 (4.85) 81.2 (3.65) 29.51 (218.14 to 20.88)
4wpRT 76.6 (5.17) 82.1 (4.14) 25.47 (214.90 to 3.97)
Abbreviations: 4wpRT, 4 weeks post-radiation therapy;CI, confidence interval; EndRT, end of radiation therapy assessment;. FACT, Functional
Assessment of Cancer Therapy.
Social, Emotional, Functional, and Physical are the core components of the FACT quality of life questionnaire. FACT-G is the sum of the 4 compo-
nents. FACT-Br is the sum of FACT-G and the brain function subscale. Higher scores indicate better function in each of these measures.
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results of these 2 small randomized studies support a phase III
study of armodafinil, especially among more fatigued patients.
It has been hypothesized that fatigue may contribute to the
worsening of cognitive function in the brain-irradiated popula-
tion. In the study by Kaleita et al, participants receiving moda-
finil also experienced statistically significant improvement in
executive functioning on the Verbal Fluency and Trail Making
tests.14 In the current study, however, there was no significant
improvement in cognitive function in either the sample as a
whole or in the more fatigued subset whose fatigue and QOL
scores benefited from armodafinil. It is unclear if the differenc-
es in outcomes in these 2 studies may be due to a difference in
participant selection between the 2 studies.
Cella et al have previously reported that a 3-point change in
the FACIT-F scale constitutes a clinically important difference in
patients with cancer-related anemia. In the current study, par-
ticipants with fatigue scores on the FACIT-F that were less than
the median score were considered to have more severe fatigue.
Of those 18 participants with more severe fatigue, 8 of them
(44%) improved by more than 3 points. Of the 24 participants
who had better thanmedian scores for fatigue at baseline, only
4 (17%) improved with armodafinil. The comparison of partici-
pants with more versus less fatigue had a P value of .0486.
Thus, these data show an encouraging trend and will be useful
to help power future prospective studies.
There are several limitations of the current study. The ac-
crued participant sample was heterogeneous and included
patients with high- and low-grade tumors as well as those re-
ceiving brain irradiation at a wide range in volumes. The study
was not adequately powered to detect treatment differences
within subpopulations. Furthermore, there has been previous
evidence to suggesting that for cognitive endpoints, the volume
of brain irradiated and the location of the targeted treatment
may predict symptoms after treatment.35 The study also did
not have central imaging review, and thus tumor volume and
location data were not obtained. With heterogeneity of tumor
locations and treatment volumes, the effects of armodafinil
may have been diluted by the inclusion of participants with
Table 6. Summary of neurocognitive outcomes (raw data) by treatment and time
Outcome Time Armodafinil Control
No Mean SD Correlation* No Mean SD Correlation*
HVLT immediate recall Baseline 26 17.6 8.04 27 21.7 6.40
EndRT 19 19.3 8.33 0.91 24 20.3 6.42 0.88
4wpRT 19 20.5 9.29 0.91 20 22.7 7.16 0.66
HVLT delayed recall Baseline 24 5.42 4.19 26 6.73 3.72
EndRT 19 6.26 4.27 0.88 23 6.78 2.95 0.84
4wpRT 19 6.05 4.03 0.96 19 7.21 3.44 0.86
HVLT true positive Baseline 26 10.1 1.97 27 10.5 1.81
EndRT 20 10.3 2.87 0.64 24 10.8 1.42 0.64
4wpRT 19 10.3 2.62 0.67 20 10.9 1.33 0.23
HVLT discrimination Baseline 26 8.81 2.68 27 9.56 2.44
EndRT 20 8.55 3.15 0.83 24 8.96 2.07 0.70
4wpRT 19 8.68 3.40 0.78 20 9.85 1.87 0.54
HVLT % savings Baseline 23 64.2 41.5 26 74.1 35.3
EndRT 19 72.3 37.4 0.71 23 78.3 19.5 0.64
4wpRT 19 67.2 36.9 0.68 19 81.5 29.8 0.40
COWA Baseline 26 12.6 5.89 27 16.5 6.62
EndRT 19 14.9 6.25 0.82 25 15.4 6.27 0.79
4wpRT 19 14.6 7.05 0.77 20 17.4 5.76 0.79
TMT_A Baseline 25 68.0 66.5 27 54.7 46.0
EndRT 20 49.2 34.1 0.62 23 59.2 61.6 0.96
4wpRT 19 50.0 43.8 0.66 19 39.8 30.6 0.82
TMT_B Baseline 24 167.6 101.6 27 142.3 100.5
EndRT 19 141.8 98.4 0.82 22 106.7 74.9 0.81
4wpRT 19 152.9 103.3 0.93 18 114.0 81.6 0.78
DST_B Baseline 26 4.77 2.60 27 5.89 2.62
EndRT 19 5.21 1.93 0.80 23 6.48 2.43 0.51
4wpRT 19 5.63 2.73 0.84 20 6.75 2.31 0.71
Abbreviations: 4wpRT, 4 weeks post radiation therapy assessment; COWA, Controlled Oral Word Association Test;EndRT, end of radiation therapy
assessment; HVLT, Hopkins Verbal Learning Test; TMT-A, Trailmaking Test A; TMT-B, Trailmaking Test B; DST-B, Digit Span Test Backwards.
Higher scores on the HVLT, COWA, and DST-B indicate better performance, while lower scores on the TMT-A and TMT-B indicate worse performance.
HVLT % savings is the percentage of the immediately recalled words that were remembered correctly after a delay of some time.
*Pearson correlations with baseline.
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smaller tumors or with tumors in locations that would lead to
less fatigue.
The heterogeneity of the sample is a major limitation of the
study. Unfortunately, the study was not powered to detect dif-
ferences in the subgroups; thus, this is a shortcoming of the
trial design as opposed to analysis. As a phase II study, howev-
er, our major goals were to show feasibility and inform us on
the power needed for a phase III study. A phase III study is cur-
rently being performed through the Alliance for Clinical Trials in
Oncology, and hopefully this larger study will be able to evalu-
ate subgroups.
There was also a possible self-selection bias of patients mo-
tivated to enroll into a study as well as physician selection pref-
erence for healthier patients to enroll; thus, these participants
may not be representative of all primary brain tumor patients
or of more fatigued patients who might have benefited from
the addition of armodafinil. However, nearly all brain tumor pa-
tients, regardless of benign or malignant histology, are known
to be affected by radiation-induced fatigue. Several studies
have shown that patients with benign or low-grade tumors
also experience fatigue with RT to the brain.36 Follow-up studies
may be best designed to enroll only patients with significant
baseline fatigue scores.
Conclusion
Armodafinil was well tolerated, and the majority of participants
completed the study and adhered to the treatment schedule.
While there was no overall difference between participants
with irradiated primary brain tumors who received armodafinil
versus placebo, those with worse baseline fatigue scores ap-
peared to have a benefit from armodafinil. A phase III study
in patients with greater baseline fatigue is needed to adequate-
ly test this treatment.
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